Not Signed In - Publications Feature VELCADE(R) (Bortezomib) For Injection Strength In Hematological Cancers
Tue, 05 Dec 2006 08:00 AM EST
... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the publication of clinical data of VELCADE in the treatment of newly diagnosed multiple myeloma (MM), MM accompanied by advanced renal failure, and mantle cell lymphoma (MCL). These data underscore the substantial activity and well-characterized safety profile of VELCADE in the treatment of hematological cancers. [click link for full article] ...
Related Topics
- Bortezomib
- Aluminum Hydroxide, Magnesium Carbonate Oral Suspension
- Acetaminophen and Aspirin and Caffeine powder
- Unusual Cancers of Childhood
- Unusual Childhood Cancers
- Dicyclomine Injection
- Aluminum and Magnesium Hydroxide
- Cortisone Injection
- Bismuth Subsalicylate
- Pseudoephedrine and Dextromethorphan
- Dimenhydrinate Injection
- Calcitonin Salmon Injection
- Strength Sports
- Ibuprofen
- Sulfamethoxazole and Trimethoprim Injection
- Strength & Weight Training
- Lactase
- Dexamethasone Injection
- Online Publications
- Progesterone Injection
email this page
print this page
bookmark this page
feedback on this page
